News from eli lilly and company A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 18, 2014, 17:45 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

FDA Approves Trulicity™ (dulaglutide), Lilly's Once-Weekly Therapy for Adults with Type 2 Diabetes

 Trulicity™ (dulaglutide), approved today by the U.S. Food and Drug Administration, is the latest Eli Lilly and Company (NYSE: LLY)...

Sep 18, 2014, 08:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

CYRAMZA™ In Combination With Paclitaxel Significantly Improves Overall Survival In Second-Line Gastric Cancer Patients

 Eli Lilly and Company (NYSE: LLY) today announced that results of the global Phase III trial of ramucirumab (CYRAMZA™) in combination...

Sep 16, 2014, 09:30 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Working Mother names Lilly to its 100 Best Companies list for 20 years

Working Mother magazine has named Eli Lilly and Company as one of its Working Mother 100 Best Companies  20 years in a row. In...

Sep 16, 2014, 08:00 ET
Lupus Foundation of America (PRNewsFoto/Eli Lilly and Lupus Found...)

"UNVEIL" Survey Reveals a Life Interrupted by Lupus

The Lupus Foundation of America and Eli Lilly and Company (NYSE: LLY) today released results from UNVEIL: understanding the impact of lupus, a new...

Sep 16, 2014, 07:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease

 Eli Lilly and Company (NYSE: LLY) and AstraZeneca today announced an agreement to co-develop and commercialize AZD3293, an oral beta secretase...

Sep 12, 2014, 08:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Lilly Announces CYRAMZA™ Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint of Overall Survival

Eli Lilly and Company (NYSE: LLY) today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA™) in combination with...

Sep 10, 2014, 07:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

European Commission grants Lilly and Boehringer Ingelheim's insulin glargine product marketing authorisation in Europe

The European Commission (EC) granted marketing authorisation for Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim's insulin glargine...

Sep 09, 2014, 08:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Lilly Highlights Latest Work in Diabetes Discovery and Development at 2014 European Association for the Study of Diabetes Annual Meeting

 Fifty abstracts designed to advance knowledge in diabetes science will be presented Sept. 15-19 by Eli Lilly and Company (NYSE: LLY) at the...

Sep 04, 2014, 08:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus® in Phase III Trials in Patients with Type 1 Diabetes

 Eli Lilly and Company's (NYSE: LLY) basal insulin peglispro (BIL) demonstrated a statistically significant lower hemoglobin A1c (HbA1c)...

Aug 26, 2014, 09:00 ET
Boehringer Ingelheim logo.  (PRNewsFoto/Eli Lilly and Company)

New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies

 Jardiance® (empagliflozin) tablets are now available by prescription in pharmacies across the United States, including Walgreens, Rite...

Aug 25, 2014, 10:15 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Lilly to Participate in Morgan Stanley 2014 Global Healthcare Conference

Eli Lilly and Company (NYSE: LLY) will participate in the Morgan Stanley 2014 Global Healthcare Conference at the Grand Hyatt in New York, NY, on...

Aug 21, 2014, 07:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Lilly's Ixekizumab Superior to Etanercept and Placebo in Phase 3 Psoriasis Studies

- Ixekizumab met all primary and key secondary objectives across three pivotal studies of 3,866 patients, the largest Phase 3...

Aug 18, 2014, 17:32 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim's Basaglar™ (insulin glargine injection)

 The U.S. Food and Drug Administration (FDA) today granted tentative approval for Basaglar™ (insulin glargine injection), which is...

Aug 04, 2014, 09:14 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Type 2 diabetes: Jentadueto® (linagliptin and metformin hydrochloride) tablets label updated to include new data on blood glucose reductions in treatment-naive adults with high baseline A1C

  The U.S. Prescribing Information for Jentadueto® (linagliptin and metformin hydrochloride) tablets now includes clinical trial data...

Aug 01, 2014, 23:26 ET
Jardiance (R)  (empagliflozin) 10 mg tablets* *The above image does not reflect the actual size of the tablet (PRNewsFoto/Eli Lilly and Company)

FDA approves Jardiance® (empagliflozin) tablets for adults with type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA)...

Jul 30, 2014, 08:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

CHMP Recommends Approval of Lilly's Humalog® 200 units/ml KwikPen®

 Eli Lilly and Company (NYSE: LLY) today announced that the Committee for Medicinal Products for Human Use (CHMP), a division of the European...

Jul 24, 2014, 06:30 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Lilly Reports Second-Quarter 2014 Results

- Second-quarter 2014 revenue declined 17 percent driven by the impact of U.S. patent expirations for Cymbalta and Evista, partially offset...

Jul 16, 2014, 08:15 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

New Study Shows Beta-Amyloid Imaging is Associated with Altered Diagnosis and Management of Alzheimer's Disease

 Eli Lilly and Company (NYSE: LLY) today announced new data showing that beta-amyloid imaging was associated with altered diagnosis and...

Jul 16, 2014, 07:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Lilly and Immunocore Enter Immunotherapy Agreement to Co-Discover and Co-Develop Novel Cancer Therapies

Eli Lilly and Company (NYSE: LLY) and Immunocore Limited today announced they have entered into a co-discovery and co-development collaboration to...

Jul 15, 2014, 02:30 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

New Data Shows Cognitive Impairment Precedes and Predicts Subsequent Functional Impairment in Patients with Mild Alzheimer's Disease

 Today, Eli Lilly and Company (NYSE:LLY) announced results from an analyses of five datasets evaluating the relationship between cognitive and...